• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Universe Pharmaceuticals Inc.

    9/20/24 4:15:32 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPC alert in real time by email

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of September 2024

     

    Commission file number: 001-40231

     

     

     

    Universe Pharmaceuticals INC
     

     

     

    265 Jingjiu Avenue
    Jinggangshan Economic and Technological Development Zone
    Ji’an, Jiangxi, China 343100
    +86-0796-8403309
    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

     

     

     

     

     

    Explanatory Note

     

    Universe Pharmaceuticals INC (the “Company”) is filing this current report on Form 6-K to report its financial results for the six months ended March 31, 2024 and to discuss its recent corporate developments.

     

    Attached as exhibits to this current report on Form 6-K are:

     

      (1) the unaudited condensed interim consolidated financial statements and related notes as Exhibit 99.1;
         
      (2) Management’s Discussion and Analysis of Financial Condition and Results of Operations as Exhibit 99.2;
         
      (3) Interactive Data File disclosure as Exhibit 101 in accordance with Rule 405 of Regulation S-T.

     

    This current report on Form 6-K is being incorporated by reference into the Form F-3 of the Company (File No. 333-268028), declared effective by the U.S. Securities and Exchange Commission on November 15, 2022.

     

    1

     

     

    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

     

    Statements in this current report with respect to the Company’s current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of the Company. Forward-looking statements include, but are not limited to, those statements using words such as “believe,” “expect,” “plans,” “strategy,” “prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,” “intend,” “seek,” “may,” “might,” “could” or “should,” and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management’s assumptions, judgments and beliefs in light of the information currently available to it. The Company cautions investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the U.S. Securities and Exchange Commission. Therefore, investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from those set forth in the forward-looking statements.

     

    All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

     

    2

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
       
    99.1   Unaudited Consolidated Financial Statements and Related Notes As of March 31, 2024 and for the Six Months Ended March 31, 2024 and 2023
    99.2   Management’s Discussion and Analysis of Financial Condition and Results of Operations
    99.3   Press Release -- Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024
    101.INS   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
    101.SCH   Inline XBRL Taxonomy Extension Schema Document.
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
    101.LAB   Inline XBRL Taxonomy Extension Labels Linkbase Document.
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
    104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

     

    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

      Universe Pharmaceuticals INC.
       
    Date: September 20, 2024 By: /s/ Gang Lai
        Gang Lai
        Chief Executive Officer

     

    4

     

    Get the next $UPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPC
    SEC Filings

    View All

    SEC Form 6-K filed by Universe Pharmaceuticals Inc.

    6-K - Universe Pharmaceuticals INC (0001809616) (Filer)

    2/11/26 4:06:12 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Universe Pharmaceuticals Inc.

    20-F - Universe Pharmaceuticals INC (0001809616) (Filer)

    1/28/26 7:34:16 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Universe Pharmaceuticals Inc.

    SCHEDULE 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

    1/7/26 3:37:31 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

    Ji'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that all conditions to the implementation of its dual-class share structure have been satisfied and that its dual-class share structure will become effective on the Nasdaq Capital Market on February 13, 2026. In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the Company's authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of pa

    2/11/26 4:05:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universe Pharmaceuticals INC Announces Share Consolidation

    Jiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company's issued and unissued share capital into one (1) ordinary share with par value of US$11.25 (the "Share Consolidation"). As a result of the Share Consolidation, each 40 pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. Th

    3/20/25 8:30:00 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

    Ji'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the "Form 20-F") and that this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Com

    2/25/25 4:10:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Leadership Updates

    Live Leadership Updates

    View All

    Universe Pharmaceuticals INC Appoints Mr. Baochang Liu as Chief Operating Officer

    Ji'an, Jiangxi, China, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company appointed Mr. Baochang Liu as its Chief Operating Officer, effective December 1, 2021. Mr. Baochang Liu has over 17 years of experience in pharmaceutical marketing. Mr. Baochang Liu has been working as the vice president of marketing and general manager of OTC department at China Shineway Pharmaceutical Group Ltd. since December 2019. Mr. Baochang Liu served as the general manager of OTC department at Chengdu Kanghong Pharmaceutical Group Co., Ltd. from November 2015 to December 2019. Prior

    12/15/21 4:30:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Universe Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

    2/14/23 2:14:41 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

    SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

    2/11/22 8:00:43 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

    SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

    12/28/21 4:10:53 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care